A detailed history of Fiduciary Trust CO transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Fiduciary Trust CO holds 236,066 shares of APLS stock, worth $6.2 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
236,066
Previous 240,286 1.76%
Holding current value
$6.2 Million
Previous $9.22 Million 26.14%
% of portfolio
0.1%
Previous 0.14%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$28.84 - $41.15 $121,704 - $173,653
-4,220 Reduced 1.76%
236,066 $6.81 Million
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $26,649 - $41,797
-700 Reduced 0.29%
240,286 $9.22 Million
Q1 2024

May 13, 2024

SELL
$55.39 - $72.47 $89,787 - $117,473
-1,621 Reduced 0.67%
240,986 $14.2 Million
Q4 2023

Feb 12, 2024

SELL
$37.14 - $64.82 $839,364 - $1.46 Million
-22,600 Reduced 8.52%
242,607 $14.5 Million
Q3 2023

Nov 14, 2023

SELL
$23.65 - $89.22 $205,967 - $777,016
-8,709 Reduced 3.18%
265,207 $10.1 Million
Q2 2023

Aug 01, 2023

SELL
$76.68 - $93.31 $20.6 Million - $25 Million
-268,375 Reduced 49.49%
273,916 $25 Million
Q1 2023

May 15, 2023

SELL
$46.59 - $66.96 $461,241 - $662,903
-9,900 Reduced 1.79%
542,291 $35.8 Million
Q4 2022

Feb 13, 2023

SELL
$43.24 - $61.04 $380,512 - $537,152
-8,800 Reduced 1.57%
552,191 $28.6 Million
Q3 2022

Nov 14, 2022

SELL
$44.76 - $69.66 $171,654 - $267,146
-3,835 Reduced 0.68%
560,991 $38.3 Million
Q1 2022

May 12, 2022

SELL
$35.46 - $54.12 $531 - $811
-15 Reduced -0.0%
564,826 $28.7 Million
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $1,075 - $1,720
-35 Reduced 0.01%
564,841 $26.7 Million
Q3 2021

Nov 12, 2021

BUY
$31.4 - $69.84 $29,076 - $64,671
926 Added 0.16%
564,876 $18.6 Million
Q2 2021

Aug 16, 2021

SELL
$40.9 - $64.9 $61,350 - $97,350
-1,500 Reduced 0.27%
563,950 $35.6 Million
Q1 2021

May 19, 2021

SELL
$40.8 - $57.39 $310,936 - $437,369
-7,621 Reduced 1.33%
565,450 $24.3 Million
Q4 2020

Jan 26, 2021

BUY
$30.79 - $57.2 $76,359 - $141,856
2,480 Added 0.43%
573,071 $32.8 Million
Q3 2020

Nov 13, 2020

SELL
$25.89 - $33.65 $569,580 - $740,300
-22,000 Reduced 3.71%
570,591 $17.2 Million
Q2 2020

Aug 13, 2020

BUY
$24.8 - $38.49 $21,799 - $33,832
879 Added 0.15%
592,591 $19.4 Million
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $56,846 - $140,703
3,174 Added 0.54%
591,712 $15.9 Million
Q4 2019

Feb 04, 2020

SELL
$22.1 - $30.8 $2.59 Million - $3.62 Million
-117,385 Reduced 16.63%
588,538 $18 Million
Q3 2019

Nov 12, 2019

BUY
$24.09 - $32.18 $40,350 - $53,901
1,675 Added 0.24%
705,923 $17 Million
Q2 2019

Aug 14, 2019

SELL
$18.0 - $25.34 $23,400 - $32,942
-1,300 Reduced 0.18%
704,248 $17.8 Million
Q4 2018

Jan 29, 2019

BUY
$11.47 - $18.71 $8.09 Million - $13.2 Million
705,548 New
705,548 $9.31 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.89B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Fiduciary Trust CO Portfolio

Follow Fiduciary Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fiduciary Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Fiduciary Trust CO with notifications on news.